Binkowska Alicja Anna, Mateja Agnieszka, Jakubowska Natalia
Institute of Psychology, Humanitas University, Sosnowiec, Poland.
Institute of Psychology, SWPS University, Warsaw, Poland.
Front Psychiatry. 2025 Aug 28;16:1646151. doi: 10.3389/fpsyt.2025.1646151. eCollection 2025.
As the global population ages, the need for effective interventions to support cognitive health in older adults is growing. Cannabidiol (CBD), a non-intoxicating component of cannabis, has emerged as a potential neuroprotective agent due to its anti-inflammatory, antioxidant, and anxiolytic properties. While preclinical studies show promising effects on hippocampal neurogenesis and cognitive performance, human trials remain limited, particularly in older populations. Existing studies have focused primarily on young, healthy adults and acute administration, often using oral routes that yield low and variable bioavailability. Furthermore, the endocannabinoid system undergoes age-related changes, potentially altering CBD efficacy in older adults. This review synthesizes current evidence on CBD and cognitive function, emphasizing age as a moderating factor, exploring pharmacokinetic challenges, and identifying key research gaps. The review calls for well-controlled trials in older adults using standardized cognitive measures, neuroimaging, and biomarker assessments. Understanding the age-specific impact of CBD on cognition is essential for evaluating its therapeutic potential in an aging society.
随着全球人口老龄化，支持老年人认知健康的有效干预措施的需求日益增长。大麻二酚（CBD）是大麻的一种无毒性成分，由于其具有抗炎、抗氧化和抗焦虑特性，已成为一种潜在的神经保护剂。虽然临床前研究显示对海马体神经发生和认知表现有良好效果，但人体试验仍然有限，尤其是在老年人群中。现有研究主要集中在年轻健康成年人以及急性给药上，通常采用生物利用度低且变化不定的口服途径。此外，内源性大麻素系统会经历与年龄相关的变化，这可能会改变CBD在老年人中的疗效。本综述综合了关于CBD与认知功能的当前证据，强调年龄作为一个调节因素，探讨药代动力学挑战，并确定关键研究差距。该综述呼吁在老年人中进行使用标准化认知测量、神经成像和生物标志物评估的严格对照试验。了解CBD对认知的年龄特异性影响对于评估其在老龄化社会中的治疗潜力至关重要。
